2025 Oncology Institute
April 30, 2025 | 8:47 AM EST
- Home
- Clinical Resources Search
- PQI in Action: Acalabrutinib (Calquence®) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Acalabrutinib (Calquence®) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Download PQI pdf 2.31MB
Last Updated: March 1, 2023
By: Hematology-Oncology Associates of Central New York , NY | South Carolina Oncology Associates, SC
About this PQI in Action
In an effort to promote higher quality patient care, NCODA created the NCODA Positive Quality Intervention (PQI) as a peer-reviewed clinical guidance resource for healthcare providers. By providing Quality Standards and effective practices around a specific aspect of cancer care, PQIs equip the entire multidisciplinary care team with a sophisticated yet concise resource for managing patients receiving oral or IV oncolytics. This PQI in Action is a follow up to the Acalabrutinib (CALQUENCE®) In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PQI and explores how the Medically Integrated Teams at Hematology-Oncology Associates of Central New York (HOACNY) and South Carolina Oncology Associates (SCOA) incorporate PQIs as part of their daily workflow. This article will discuss how utilizing the Acalabrutinib (CALQUENCE®) In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PQI elevates patient care.
More About This PQI in Action
Find a PQIPQI
PQI: Acalabrutinib (Calquence®) In Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Last Updated: March 12, 2023